AUR112

AUR112 is a small molecule inhibitor of WEE1 kinase, developed by Aurigene Discovery Technologies for the treatment of advanced solid tumors. WEE1 is a nuclear kinase that acts as a key regulator of the G2/M cell cycle checkpoint by phosphorylating and inhibiting CDC2 (CDK1). By blocking WEE1 activity, AUR112 prevents cancer cells from pausing in the G2 phase to repair DNA damage, forcing them into premature mitosis. This leads to genomic instability and cell death, a process known as mitotic catastrophe. This therapeutic approach is especially potent in TP53-mutant cancers, which lack a functional G1 checkpoint and are highly dependent on the G2 checkpoint for DNA repair. AUR112 is currently undergoing Phase 1 clinical evaluation.